Tunisia Habib Toumi, CEO of the Tunisian National Social Security Fund (CNSS), discusses implementing universal healthcare coverage, restoring the financial equilibrium of the fund, and managing the continuous improvement of services provided in the CNSS policlinics. Can you describe the operational characteristics of the Tunisian National Social Security Fund (CNSS)? “Concerning…
India At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based pharmaceutical companies in India, putting the patient at the center of all that they do is part of their DNA. On the occasion of their 51st Annual Day celebrations, experts met to discuss the need to…
Bulgaria Prof. Dr. Kamen Plochev, Dr. M. Sc., recently appointed as the governor of the National Health Insurance Fund in Bulgaria, discusses the key issues he has identified for the Bulgarian healthcare system as well as how he intends to tackle them and ultimately establish a more efficient and transparent organization.…
India Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges of the current pricing climate, and the ultimate goal of providing affordable and accessible medicines to the nation’s roughly 1.3…
Bulgaria Stanimir Hasurdjiev explains the key role of the National Patients’ Organization (NPO) in Bulgaria and discusses the main areas that he is working on to ensure that patients are heard and can benefit from the best treatments and care available at a reasonable price. You are working in different…
Austria Philipp Lindinger, managing director of Austromed, the Austrian association for medical devices and in-vitro diagnostics, discusses the organization’s purpose, the impact of European regulation on medical devices on the sector, the importance of a strong notified body system, and the steps required to stimulate future growth within the Austrian medical…
India The secretary-general of the Indian Drug Manufacturers Association (IDMA) gives his insight into the current state of the Indian pharma industry, the IDMA’s role in raising the quality of Indian-made products, and the country’s vital role in the global supply chain. IDMA is celebrating its 55th anniversary in India and…
Brazil In an exclusive interview, Minister of Health of Brazil Ricardo Barros provides insights into his main achievements since being appointed in May 2016 and his key priorities to further improve the management and delivery of Brazil’s public health system, while highlighting his expectations for pharmaceutical companies implanted in the country.…
Austria Martin Tiani, CEO of Tiani Spirit, the global leader in Integrating the Healthcare Enterprise (IHE), discusses the importance of interoperability within electronic health information exchange (HIE) and the challenges e-health faces, especially for the company as they adapt to differing regulations in various nations. Furthermore, he highlights the grapevine initiative (grapevineworld.com) for…
Canada Michael Tremblay, president and CEO of Astellas Pharma Canada, Inc., draws upon his four decades of experience within the Canadian pharmaceutical industry to discuss his thoughts on the need for Canada to move away from a ‘silo-ed’ approach to healthcare spending, the value that Astellas has been bringing to patients…
Canada Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB), Canada’s federal price regulator for patented medicines, highlights the PMPRB’s mandate to protect consumers against excessive prices for patented drugs, the rationale behind the recent proposed changes to their guidelines, and the role PMPRB can play within Canada’s…
Canada Jim Keon, President of the CGPA, discusses how the Canadian generics industry is adapting to the current period of political transition and how it engages in talks with the government and other stakeholders to educate them about the costly and complex process of generic drug production. Jim, we had the…
See our Cookie Privacy Policy Here
